Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Blachly

Showing results (91-100 of 144) with videos related to

Pageof 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2026
Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with IbrutinibShanmugapriya Thangavadivel, Jami Shaffer, Shrilekha Misra, et al.
Bioinformatics (Oxford, England)|September 19, 2025
qcCHIP: an R package to identify clonal hematopoiesis variants using cohort-specific data characteristicsXiang Liu, Yi-Han Tang, James Blachly, et al.
Blood Advances|November 30, 2021
Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemiaSydney Fobare, Jessica Kohlschmidt, Hatice Gulcin Ozer, et al.
Oncotarget|April 17, 2017
The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemiaCecelia R Miller, Amy S Ruppert, Sydney Fobare, et al.
Cancer Discovery|November 28, 2019
Resistance Mechanisms to SYK Inhibition in Acute Myeloid LeukemiaAnjali Cremer, Jana M Ellegast, Gabriela Alexe, et al.
Leukemia|June 7, 2018
NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcomeAnn-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, et al.
American Journal of Hematology|August 11, 2020
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromeCaner Saygin, Karilyn Larkin, James S Blachly, et al.
Frontiers in Immunology|April 20, 2026
Reversible cerebral vasoconstriction syndrome following ciltacabtagene autoleucel therapy for relapsed multiple myeloma: a case reportTuan L Phan, Adel Hijazi, Romi Xi, et al.
Clinical and Translational Science|July 28, 2019
Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AMLDaelynn R Buelow, Stanley B Pounds, Yong-Dong Wang, et al.
Science Advances|September 16, 2022
Targeting OXPHOS de novo purine synthesis as the nexus of <i>FLT3</i> inhibitor-mediated synergistic antileukemic actionsPu Zhang, Lindsey T Brinton, Mehdi Gharghabi, et al.
Pageof 15

Showing results (91-100 of 144) with videos related to

Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2026
Single-Cell RNA-seq Analysis Reveals Distinct Tumor and Immunosuppressive T-Cell Phenotypes in Patients with CLL Treated with IbrutinibShanmugapriya Thangavadivel, Jami Shaffer, Shrilekha Misra, et al.
Bioinformatics (Oxford, England)|September 19, 2025
qcCHIP: an R package to identify clonal hematopoiesis variants using cohort-specific data characteristicsXiang Liu, Yi-Han Tang, James Blachly, et al.
Blood Advances|November 30, 2021
Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemiaSydney Fobare, Jessica Kohlschmidt, Hatice Gulcin Ozer, et al.
Oncotarget|April 17, 2017
The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemiaCecelia R Miller, Amy S Ruppert, Sydney Fobare, et al.
Cancer Discovery|November 28, 2019
Resistance Mechanisms to SYK Inhibition in Acute Myeloid LeukemiaAnjali Cremer, Jana M Ellegast, Gabriela Alexe, et al.
Leukemia|June 7, 2018
NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcomeAnn-Kathrin Eisfeld, Jessica Kohlschmidt, Krzysztof Mrózek, et al.
American Journal of Hematology|August 11, 2020
A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromeCaner Saygin, Karilyn Larkin, James S Blachly, et al.
Frontiers in Immunology|April 20, 2026
Reversible cerebral vasoconstriction syndrome following ciltacabtagene autoleucel therapy for relapsed multiple myeloma: a case reportTuan L Phan, Adel Hijazi, Romi Xi, et al.
Clinical and Translational Science|July 28, 2019
Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AMLDaelynn R Buelow, Stanley B Pounds, Yong-Dong Wang, et al.
Science Advances|September 16, 2022
Targeting OXPHOS de novo purine synthesis as the nexus of <i>FLT3</i> inhibitor-mediated synergistic antileukemic actionsPu Zhang, Lindsey T Brinton, Mehdi Gharghabi, et al.
Pageof 15